The DARE Warfarin CER Study

NCT03271450 · clinicaltrials.gov ↗

UNKNOWN

Status

416000

Enrollment

OTHER

Sponsor class

Conditions

Deep Venous Thrombosis
Pulmonary Embolism

Interventions

DRUG: Dabigatran: extended treatment (e.g at least 90 days)
DRUG: Dabigatran: extended treatment (e.g at least 180 days)
DRUG: Dabigatran: extended treatment (e.g at least 270 days)
DRUG: Apixaban: extended treatment (e.g at least 90 days)
DRUG: Apixaban: extended treatment (e.g at least 180 days)
DRUG: Apixaban: extended treatment (e.g at least 270 days)
DRUG: Rivaroxaban: extended treatment (e.g at least 90 days)
DRUG: Rivaroxaban: extended treatment (e.g at least 180 days)
DRUG: Rivaroxaban: extended treatment (e.g at least 270 days)
DRUG: Edoxaban: extended treatment (e.g at least 90 days)
DRUG: Edoxaban: extended treatment (e.g at least 180 days)
DRUG: Edoxaban: extended treatment (e.g at least 270 days)
DRUG: Warfarin: extended treatment (e.g at least 90 days)
DRUG: Warfarin: extended treatment (e.g at least 180 days)
DRUG: Warfarin: extended treatment (e.g at least 270 days)

Sponsor

Brigham and Women's Hospital

Collaborators

[object Object]
[object Object]